Andrx abandons brands in favor of generics, ends Pfizer deal
The company stated the plan realigns its business strategy, focusing on its core competencies of formulation development of controlled-release pharmaceuticals and distribution, and divesting or seeking other strategic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.